Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy and Safety of Two Doses of Liarozole vs. Placebo for the Treatment of Lamellar Ichthyosis
This study has been completed.
Study NCT00282724   Information provided by Barrier Therapeutics/ Stiefel, a GSK Company
First Received: January 20, 2006   Last Updated: June 2, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Ichthyosis, Lamellar
Additional conditions recognized in this trial
Ichthyosis
More general conditions related to this trial
Congenital Abnormalities
Genetic Diseases, Inborn
Ichthyosiform Erythroderma, Congenital
Infant, Newborn, Diseases
Keratosis
Skin Abnormalities
Skin Diseases
Skin Diseases, Genetic
Interventions listed in this trial
Liarozole
More general drug interventions related to this trial
Androgen Antagonists
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Dermatologic Agents
Enzyme Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Barrier Therapeutics/ Stiefel, a GSK Company


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services